Furthermore we have recently we showed that HO-1 is in fact down-regulated in AML by their constitutively active NF-κB activity present, and that inhibiting NF-κB brings HO-1 levels back to more normal levels, providing further secondary protection for AML cells against NF-κB inhibition. Here, NFKB1 is linked to acute myeloid leukemia.